324 related articles for article (PubMed ID: 31447130)
1. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
[TBL] [Abstract][Full Text] [Related]
2. A tailored approach to refractory severe Mepolizumab-associated headache: a case study.
Salerni C; Baccelli A; Parazzini EM; Rinaldo R; Centanni S
J Asthma; 2024 Jun; 61(6):649-652. PubMed ID: 38088891
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mepolizumab in a Chinese population with severe asthma: a phase III, randomised, double-blind, placebo-controlled trial.
Chen R; Wei L; Dai Y; Wang Z; Yang D; Jin M; Xiong C; Li T; Hu S; Song J; Chan R; Kumar S; Abdelkarim A; Zhong N
ERJ Open Res; 2024 May; 10(3):. PubMed ID: 38770009
[TBL] [Abstract][Full Text] [Related]
5. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ; Heaney LG; Humbert M; Kent BD; Shavit A; Hiljemark L; Olinger L; Cohen D; Menzies-Gow A; Korn S;
Lancet; 2024 Jan; 403(10423):271-281. PubMed ID: 38071986
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation.
Reilly C; Raja A; Anilkumar P; Sullivan J; White L; Bahron A; Marsh J; Mansur AH
J Asthma; 2024 Jun; 61(6):561-573. PubMed ID: 38088937
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Mepolizumab, Benralizumab, and Dupilumab among Patients with Difficult-to-Control Asthma: A Multicenter Retrospective Propensity-matched Analysis.
Kearney CM; Sangani R; Shankar D; O'Connor GT; Law AC; Walkey AJ; Bosch NA
Ann Am Thorac Soc; 2024 Jun; 21(6):866-874. PubMed ID: 38241013
[No Abstract] [Full Text] [Related]
8. Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
Bagnasco D; Povero M; Pradelli L; Brussino L; Rolla G; Caminati M; Menzella F; Heffler E; Canonica GW; Paggiaro P; Senna G; Milanese M; Lombardi C; Bucca C; Manfredi A; Canevari RF; Passalacqua G;
World Allergy Organ J; 2021 Feb; 14(2):100509. PubMed ID: 33598095
[TBL] [Abstract][Full Text] [Related]
9. Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy.
Kayser MZ; Suhling H; Fuge J; Hinze CA; Drick N; Kneidinger N; Behr J; Taube C; Welte T; Haasler I; Milger K
BMC Pulm Med; 2024 Mar; 24(1):149. PubMed ID: 38515071
[TBL] [Abstract][Full Text] [Related]
10. The role of ACT score in mepolizumab discontinuation.
Solanki N; Beck B; Labadia M; Smith K; Peterson L; King S; Micklewright S; Pennington E; Farooq S; Zhang P; Aronica M; Zein J; Khatri S; Comhair S; Erzurum S
J Asthma; 2024 Jun; 61(6):550-560. PubMed ID: 38064231
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and safety of biological therapy in patients with severe asthma in a real clinical practice].
Sergeeva GR; Emelyanov AV
Ter Arkh; 2024 Apr; 96(3):240-245. PubMed ID: 38713038
[TBL] [Abstract][Full Text] [Related]
12. Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma.
Silver J; Steffens A; Chastek B; Deb A
J Asthma Allergy; 2024; 17():261-271. PubMed ID: 38544676
[TBL] [Abstract][Full Text] [Related]
13. In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control.
Stanbrook MB
Ann Intern Med; 2024 Apr; 177(4):JC43. PubMed ID: 38560905
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia.
Khoury P; Makiya MA; Rahim R; Bowman A; Espinoza D; Schiffenbauer A; Koch M; Anderson C; Constantine G; Maric I; Sun X; Pittaluga S; Brown T; Ware JM; Wetzler L; Fay MP; Klion AD
J Allergy Clin Immunol; 2024 Mar; 153(3):821-830.e6. PubMed ID: 37951310
[TBL] [Abstract][Full Text] [Related]
15. MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab.
Bourdin A; Chupp G; Jackson DJ; Cohen D; Emerath U; Shavit A; Kurdyukova Y; Menzies-Gow A
J Allergy Clin Immunol Pract; 2024 Apr; ():. PubMed ID: 38677588
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthma.
Perez-de-Llano L; Scelo G; Canonica GW; Chen W; Henley W; Larenas-Linnemann D; Peters MJ; Pfeffer PE; Tran TN; Ulrik CS; Popov TA; Sadatsafavi M; Hew M; Máspero J; Gibson PG; Christoff GC; Fitzgerald JM; Torres-Duque CA; Porsbjerg CM; Papadopoulos NG; Papaioannou AI; Heffler E; Iwanaga T; Al-Ahmad M; Kuna P; Fonseca JA; Al-Lehebi R; Rhee CK; Koh MS; Cosio BG; Perng Steve DW; Mahboub B; Menzies-Gow AN; Jackson DJ; Busby J; Heaney LG; Patel PH; Wang E; Wechsler ME; Altraja A; Lehtimäki L; Bourdin A; Bjermer L; Bulathsinhala L; Carter V; Murray R; Beastall A; Denton E; Price DB
Ann Allergy Asthma Immunol; 2024 May; 132(5):610-622.e7. PubMed ID: 38151100
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study.
Pham DD; Lee JH; Kwon HS; Song WJ; Cho YS; Kim H; Kwon JW; Park SY; Kim S; Hur GY; Kim BK; Nam YH; Yang MS; Kim MY; Kim SH; Lee BJ; Lee T; Park SY; Kim MH; Cho YJ; Park C; Jung JW; Park HK; Kim JH; Moon JY; Bhavsar P; Adcock I; Chung KF; Kim TB
Lung; 2024 Feb; 202(1):41-51. PubMed ID: 38252134
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and predictive clinical scores for asthma exacerbations in childhood.
Forno E; Fuhlbrigge A; Soto-Quirós ME; Avila L; Raby BA; Brehm J; Sylvia JM; Weiss ST; Celedón JC
Chest; 2010 Nov; 138(5):1156-65. PubMed ID: 20472862
[TBL] [Abstract][Full Text] [Related]
19. Development and Dynamic Responsiveness of the Acute Asthma Exacerbation Survey in Patients With Moderate to Severe Disease.
Laurenzo SA; Townsend EA; Lane Starr NM; Wollet LJ; Castro M; Jarjour NN; Sorkness CA; Lee KE; Denlinger LC
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3425-3434.e4. PubMed ID: 37453571
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab.
Bagnasco D; Bondi B; Caminati M; Nicola S; Pini L; Milanese M; Brussino L; Senna G; Canonica GW; Braido F
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
